December 23, 2011 -- BioTime of the US has signed an agreement with USCN Life Science China, giving BioTime an option to license USCN’s antibody-producing cell lines. BioTime and its OncoCyte subsidiary may use the cell lines to manufacture the antibody components of PanC-Dx, a novel technology designed to detect various cancers during routine check-ups. More details....
Stock Symbol: (AMEX: BTX)
